Not investment advice. FilingSight is an automated analytical research tool, not a registered investment advisor. Ratings and scores are quantitative analytical classifications, not buy or sell recommendations. Nothing here is personalized to your circumstances. Investing involves risk of loss — consult a licensed professional. See full disclosures.
Costco Wholesale
COSTConsumer StaplesGenerated Sep 5, 2026, 01:36 PM UTC
COST (Costco Wholesale) analytical snapshot. Revenue grew +8.2% YoY to $275.24B. 5-year revenue CAGR +7.0%; 10y CAGR +9.8%. Net margin at 2.94% (expanding ▲). Market cap $406.11B at $915.74 per share. Trailing P/E 50.29, P/S 1.48, P/B 12.12. EV/Operating income ≈ 37.93 (EV $393.78B). Risk: Moderate. Macro: Risk-on · Supportive. Composite analytical score -20 (data confidence 83%). Descriptive analytics from public filings — not investment advice.
Free SEC analysis
— computed from SEC filings, free to readFilings & Ownership
Latest annual report (10-K) filed Oct 8, 2025. Latest quarterly report (10-Q) filed Jun 3, 2026. 14 recent 8-K material-event filings in the index.
- Latest annual report (10-K) filed Oct 8, 2025.
- Latest quarterly report (10-Q) filed Jun 3, 2026.
- 14 recent 8-K material-event filings in the index.
- Recent insider Form 4s: 0 buy vs 3 sell transactions — net selling $2.3M.
- ~10,000+ recent 13F-HR filings reference Costco Wholesale; broad institutional reporting.
- Recent filers include Carroll Investors, Inc, Game Plan Financial Advisors, LLC, Silver Grove Financial Group, Inc..
- 20 recent 13G passive institutional ownership notices.
| Filer | Form | Filed |
|---|---|---|
| Carroll Investors, Inc | 13F-HR | Apr 28, 2022 |
| Game Plan Financial Advisors, LLC | 13F-HR | Apr 12, 2024 |
| Silver Grove Financial Group, Inc. | 13F-HR | Feb 13, 2026 |
| Foresters Asset Management Inc. | 13F-HR | Nov 14, 2016 |
| RG CAPITAL MANAGEMENT LP | 13F-HR | Feb 13, 2003 |
| Insider | Date | Net | Buys/Sells |
|---|---|---|---|
| DENMAN KENNETH D | Jun 25, 2026 | -$847.3K | 0/1 |
| Frates Caton | Apr 1, 2026 | -$695.1K | 0/1 |
| Adamo Claudine | Mar 11, 2026 | -$732.2K | 0/1 |
| Date | Form | Description |
|---|---|---|
| Jul 8, 2026 | 8-K | 8-K |
| May 28, 2026 | 8-K | 8-K |
| Apr 15, 2026 | 8-K | 8-K |
| Mar 5, 2026 | 8-K | 8-K |
| Jan 21, 2026 | 8-K | 8-K |
| Dec 11, 2025 | 8-K | 8-K |
| Oct 20, 2025 | 8-K | 8-K |
| Oct 15, 2025 | 8-K | 8-K |
SEC Filing Deep-Analysis
2 risk signal(s), 1 positive signal(s), 2 watch item(s) detected from XBRL filing diff analysis. 2 risk signal(s) detected versus 1 positive signal(s). The balance of evidence suggests elevated filing-specific risk that warrants monitoring in subsequent filings.
- Material weakness in internal controls: The term "material weakness" "internal control" appears in 5 recent filing(s) (vs 2 in the prior period). This risk language is ongoing.
- NEW: Restatement of financial statements in latest filing: The term "restatement of" "previously issued" appears in recent 10-K/10-Q filings but was NOT present in the prior 24-month period. This is a new risk disclosure that warrants attention. Found in 1 filing(s).
- Operating cash flow exceeds net income: OCF is 1.65x net income, indicating high earnings quality — cash conversion is strong and accruals are not inflating reported profits.
- NEW: Impairment charge: Impairment charge appears in recent filings but not in the prior 24-month period. Monitor for materiality.
- NEW: Restructuring: Restructuring appears in recent filings but not in the prior 24-month period. Monitor for materiality.
- Endogenous analysis: 2 risk signal(s) detected versus 1 positive signal(s). The balance of evidence suggests elevated filing-specific risk that warrants monitoring in subsequent filings.
- 5 new XBRL disclosure(s) in latest filing — expanding reporting scope.
- 20 disclosure(s) dropped from prior year — reduced reporting granularity.
- 3 new risk-language term(s) detected in filing text: Restatement of financial statements, Impairment charge, Restructuring.
- Ongoing high-severity risk language: Material weakness in internal controls.
| Metric | Prior year | Latest year | Change | % Change |
|---|---|---|---|---|
| Revenue | $254.45B | $275.24B | $20.78B | +8.2% |
| Gross profit | — | $16.46B | — | — |
| Operating income | $9.29B | $10.38B | $1.10B | +11.8% |
| Net income | $7.37B | $8.10B | $732.0M | +9.9% |
| Operating cash flow | $11.34B | $13.34B | $2.00B | +17.6% |
| Capex | $4.71B | $5.50B | $788.0M | +16.7% |
| Total assets | $69.83B | $77.10B | $7.27B | +10.4% |
| Total liabilities | $46.21B | $47.94B | $1.73B | +3.7% |
| Long-term debt | $5.79B | $5.71B | $-81.0M | -1.4% |
| Cash & equivalents | $9.91B | $14.16B | $4.25B | +43.0% |
| Stockholders equity | $23.62B | $29.16B | $5.54B | +23.5% |
| Inventory | $18.65B | $18.12B | $-531.0M | -2.8% |
| SG&A expense | $22.81B | $24.97B | $2.16B | +9.5% |
| Interest expense | $169.0M | $154.0M | $-15.0M | -8.9% |
| Type | Concepts |
|---|---|
| Added | AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount, AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax, AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax, NumberOfReportableSegments, RepaymentsOfDebt |
| Removed | AccruedInsuranceCurrentAndNoncurrent, AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment, BuildingsAndImprovementsGross, ConstructionInProgressGross, CreditAndDebitCardReceivablesAtCarryingValue, CurrentFederalTaxExpenseBenefit, CurrentForeignTaxExpenseBenefit, CurrentStateAndLocalTaxExpenseBenefit, DebtInstrumentRedemptionPricePercentage, DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss |
| Term | Severity | Recent | Prior | Status |
|---|---|---|---|---|
| Material weakness in internal controls | high | 5 | 2 | Ongoing |
| Restatement of financial statements | high | 1 | 0 | NEW |
| Impairment charge | medium | 5 | 0 | NEW |
| Restructuring | medium | 5 | 0 | NEW |
| Off-balance sheet arrangements | medium | 5 | 2 | Ongoing |
Fundamentals
Revenue grew +8.2% YoY to $275.24B. 5-year revenue CAGR +7.0%; 10y CAGR +9.8%. Net margin at 2.94% (expanding ▲).
- Revenue grew +8.2% YoY to $275.24B.
- 5-year revenue CAGR +7.0%; 10y CAGR +9.8%.
- Net margin at 2.94% (expanding ▲).
- Return on equity 27.77%, ROA 10.50%, ROIC 29.77%.
- Gross margin 0.00%, operating margin 3.77%.
- Free cash flow margin 2.85% ($7.84B).
- Net income up ▲ +9.9% YoY.
- Debt/equity 0.20, current ratio 1.07, net debt -$12.33B.
- Asset turnover 3.18 — capital efficiency.
| FY | Revenue | Rev YoY | Gross% | Op% | Net% | FCF | ROE% |
|---|---|---|---|---|---|---|---|
| 2024 | $254.45B | +5.0% | 0.00 | 3.65 | 2.90 | $6.63B | 31.19 |
| 2025 | $275.24B | +8.2% | 0.00 | 3.77 | 2.94 | $7.84B | 27.77 |
| Quarter end | Revenue | YoY | QoQ | Net margin |
|---|---|---|---|---|
| Sep 1, 2024 | $254.45B | — | — | — |
| Nov 24, 2024 | $62.15B | — | -75.6% | 2.89% |
| Feb 16, 2025 | $63.72B | — | +2.5% | 2.81% |
| May 11, 2025 | $63.20B | — | -0.8% | 3.01% |
| Nov 23, 2025 | $67.31B | — | +6.5% | 2.97% |
| Feb 15, 2026 | $69.60B | — | +3.4% | 2.92% |
Pro analysis — preview
— score, signals & key metrics shown; full reasoning lockedValuation
Market cap $406.11B at $915.74 per share. Trailing P/E 50.29, P/S 1.48, P/B 12.12. EV/Operating income ≈ 37.93 (EV $393.78B).
- Market cap $406.11B at $915.74 per share.
Price & Technicals
Price $915.74 — downtrend (below 200-DMA); 1-month momentum negative. RSI(14) 37.49.
- Price $915.74 — downtrend (below 200-DMA); 1-month momentum negative.
Macro & Rates
Risk-on · Supportive. Real GDP growth 1.50% (quarterly, as of Apr 1, 2026). CPI inflation +3.3% YoY. Fed funds rate 3.63%, 10Y Treasury 4.77%.
- Market regime: Risk-on · Supportive.
Risk Scorecard
Composite risk Moderate. Leverage debt/equity 0.20 (low). Liquidity current ratio 1.07 (adequate).
- Composite risk: Moderate.
See the full picture behind every stock
Unlock the complete 10-year fundamentals, DCF & Graham intrinsic value, 13F/13D ownership flow, risk scorecard, multi-analyst bull/bear debate — plus watchlist alerts and your research workspace. Start with a 14-day Pro trial.
3 sections free · 4 Pro previews · composite -20
Macro exposure
Defensive · Low sensitivityMacro regime: Risk-on · Supportive. Costco Wholesale is a defensive name (low macro sensitivity) — a supportive backdrop, though defensives lag risk-on tapes.
Analytical read
deterministic previewRevenue grew **+8.2%** YoY to $275.24B..
Peer comparison
Defensive groupHow COST stacks up against tracked peers with similar macro sensitivity — by analytical score and macro exposure.
| Company | Score | Macro |
|---|---|---|
| DexCom Inc. DXCM | 21 | Neutral |
| Bristol-Myers Squibb BMY | 19 | Neutral |
| Gilead Sciences GILD | 10 | Neutral |
| Regeneron Pharmaceuticals REGN | 10 | Neutral |
| Johnson & Johnson JNJ | 10 | Neutral |
| Eli Lilly & Co. LLY | 9 | Neutral |
| Biogen Inc. BIIB | 7 | Neutral |
| Abbott Laboratories ABT | 7 | Neutral |
| Zoetis Inc. ZTS | 6 | Neutral |
| HCA Healthcare HCA | 6 | Neutral |
| Thermo Fisher Scientific TMO | 3 | Neutral |
| Coca-Cola Co. KO | 3 | Neutral |
| Intuitive Surgical Inc. ISRG | 2 | Neutral |
| Danaher Corp. DHR | 1 | Neutral |
| Illumina Inc. ILMN | 0 | Neutral |
| Merck & Co. MRK | 0 | Neutral |
| Cigna Group CI | 0 | Neutral |
| Vertex Pharmaceuticals VRTX | 0 | Neutral |
| AbbVie Inc. ABBV | -2 | Neutral |
| Colgate-Palmolive CL | -4 | Neutral |
| CVS Health Corp. CVS | -6 | Neutral |
| Kroger Co. KR | -8 | Neutral |
| Amgen Inc. AMGN | -10 | Neutral |
| Procter & Gamble PG | -10 | Neutral |
| Pfizer Inc. PFE | -11 | Neutral |
| Mondelez International MDLZ | -13 | Neutral |
| Sysco Corp. SYY | -15 | Neutral |
| Moderna Inc. MRNA | -19 | Neutral |
| Walmart Inc. WMT | -20 | Neutral |
| Costco Wholesale COST● you | -20 | Neutral |
| UnitedHealth Group UNH | -21 | Neutral |
| Hershey Co. HSY | -22 | Neutral |
| PepsiCo Inc. PEP | -22 | Neutral |
| Kimberly-Clark Corp. KMB | -24 | Neutral |